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a-Melanocyte stimulating hormone (a-MSH) has pig-
mentary, anti-in£ammatory, antipyretic, and general
immunomodulatory roles. It can oppose several cyto-
kines including tumor necrosis factor-a in a number of
tissues, including skin. We have previously shown that
a-MSH can inhibit tumor necrosis factor-a stimulated
intercellular adhesion molecule 1 upregulation and nu-
clear factor jB (NFjB) transcription factor activation
in melanocyte and melanoma cells. It is thought, how-
ever, that this MSH biology may also extend to other
cells of the skin and in this study we extend our work
to keratinocytes.We have investigated in detail the abil-
ity of three a-MSH peptides to inhibit tumor necrosis
factor a stimulated NFjB activation in nonpigmentary
HaCaT keratinocytes (a-MSH, L-Lys-L-Pro-L-Val, and
L-Lys-L-Pro-D-Val) and two adrenocorticotropic hor-
mone (ACTH) peptides (1^17 and 1^39), reported to be
present in skin tissue. NFjB/p65 activation was ana-
lyzed by electrophoretic mobility shift assay and im-
muno£uorescent microscopy. a-MSH, L-Lys-L-Pro-L-
Val, and L-Lys-L-Pro-D-Val all signi¢cantly inhibited
tumor necrosis factor a stimulated NFjB activation,
whereas ACTH 1^17 and 1^39 did not, in the HaCaT
keratinocytes. MSH peptides and ACTH 1^39 were ef-
fective, however, at inhibiting NFjB activation in nor-
mal human keratinocytes. Immunolabeling of inhibitor
jBa of NFjB (IjBa) revealed an abnormal localization
to the nucleus of HaCaTcells, which was una¡ected by
MSH/ACTH peptides. In contrast, normal human kera-
tinocytes showed a normal IjBa distribution that re-
sponded to MSH/ACTH with nuclear translocation.
Our data support previous work on the role of MSH/
ACTH peptides as immunomodulatory/anti-in£amma-
tory regulators, and extend this work to keratinocytes
identifying a novel IjBa mechanism and extends ¢nd-
ings to ACTH peptides, identifying an abnormal IjBa
mechanism in the immortal HaCaT versus normal kera-
tinocyte. Key words: transcription factor/in£ammation/mela-
nocortin/skin. J Invest Dermatol 119:1244 ^1253, 2002
a-Melanocyte stimulating hormone (a-MSH) is a 13 amino acid
peptide that arises by proteolytic cleavage of the proopiomelano-
cortin (POMC) pro-hormone precursor molecule. The peptide is
produced in a number of tissues including the intermediate lobe
of the pituitary, gut, and skin (Eberle, 1988). a-MSH has many
biologic e¡ects, most notably on eumelanogenic pigmentation
of the skin (Eberle, 2000). An increasing literature also docu-
ments other extra-pigmentary roles, including inhibition of fe-
ver, in£ammation, and immunomodulation (Hiltz and Lipton,
1989; Hiltz et al, 1991; Lipton et al, 1991; 1998; Martin et al, 1991;
Catania and Lipton, 1993;Watanabe et al, 1993; Ceriani et al, 1994;
Lipton and Catania, 1997; Rajora et al, 1997; Ichiyama et al, 1999b;
Taherzadeh et al, 1999). In human skin, a-MSH is immunoreactive
in keratinocytes and melanocytes and studies have previously
suggested a regulatory involvement in melanocyte pigmentation
and proliferation (Hedley et al, 1998a). a-MSH signaling is trans-
mitted via a family of speci¢c melanocortin (MC) G-protein
linked receptors. Five MC receptors have been cloned to date
(MC-1R to MC-5R) and in skin MC-1R is expressed on cuta-
neous melanocytes and melanoma cells (Chhajlani andWikberg,
1992; Mountjoy et al, 1992). MC-1R, however, is also expressed
on other cell types including keratinocytes, endothelial cells,
monocytes, and neural cells (Bhardwaj et al, 1997; Hartmeyer
et al, 1997).
The mechanism by which a-MSH acts as an anti-in£amma-
tory peptide is not completely resolved. It is known to inhibit
proin£ammatory cytokine production/action e.g., tumor necrosis
factor-a (TNFa) and interleukin-1b (IL-1b);Weiss et al, 1991], and
to increase anti-in£ammatory cytokine production (e.g., IL-10;
Bhardwaj et al, 1996).We have previously reported a-MSH to have
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a role in cutaneous immunomodulation, showing an ability to
inhibit TNFa upregulation of surface intercellular adhesion mo-
lecular 1 (ICAM-1) expression (prerequisite for T lymphocyte
binding) in melanocytes and melanoma cells (Hedley et al,
1998b; Morandini et al, 1998).We have also demonstrated that a-
MSH inhibits the TNFa activation of the nuclear factor kB
(NFkB) transcription factor in ocular and cutaneous melanocytes
and melanoma cells (Haycock et al, 1999a; 1999b). Acute NFkB
activation is responsible for expression of several in£ammatory
and immune system genes, and hence inhibition by a-MSH is
one signaling pathway by which this peptide may exert anti-in-
£ammatory control. Furthermore, we have also demonstrated
that a-MSH (and peptide derivatives) decrease acute intracellular
generation of reactive oxygen species, directly detectable as perox-
ide species (and indirectly as perturbation of glutathione peroxi-
dase activity), in both a melanoma and a keratinocyte cell line
(HaCaT) (Haycock et al, 2000). Peroxide species are reported to
be a mechanism by which NFkB is rapidly activated, and there-
fore inhibition by the MSH peptides may explain signaling con-
trol over NFkB activation and ICAM-1 expression. An MSH
attenuation of the ICAM-1 response to TNFa would be consis-
tent with protection of cells from the immune system, and we
have recently shown that a-MSH reduces the ability of melano-
ma cells to bind to T lymphocytes (Hedley et al, 2000). In addi-
tion to the native a-MSH (1^13) peptide, several MSH peptide
derivatives are reported to possess anti-in£ammatory biology.
The most notable of these is the carboxyl-terminal tripeptide
MSH 11^13 (Lys-Pro-Val). Indeed it is thought that this is the
minimum obligatory MSH sequence needed to demonstrate an
antiin£ammatory e¡ect in vivo (Hiltz and Lipton, 1989; Hiltz
et al, 1991).
A number of previous studies report on the MSH responsive-
ness of pigmentary skin cells; however, it is known that the im-
munoregulatory biology displayed by a-MSH is reported for a
number of dissimilar tissues, and so it is feasible that the anti-in-
£ammatory biology of the MSH peptides with respect to skin is
not restricted solely to melanocytes and melanoma cells. Further-
more, it has recently been reported that adrenocorticotropic hor-
mone (ACTH) and a truncated peptide (ACTH 1^17) are
present in skin tissue and that ACTH 1^17 binds to the MC-1R
(Tsatmali et al, 1999). Therefore in this study we investigated MC-
1R and MC-2R expression in the human HaCaT keratinocyte
cell line and in normal human keratinocytes and investigated
whether MSH/ACTH peptides were able to in£uence the re-
sponse of cells to proin£ammatory cytokine stimulation
assessed by an ability to inhibit TNFa-stimulated NFkB/p65
activity.
MATERIALS AND METHODS
Cell culture The HaCaT human keratinocyte cell line was kindly
supplied by Professor N.E. Fusenig (Institute of Biochemistry, German
Cancer Research Center, Heidelberg, Germany). Cells were grown in 24-
well plates in Dulbecco’s modi¢ed Eagle’s medium (Sigma, Poole, U.K.)
supplemented with 5% fetal bovine serum (Labtech International, U.K.),
2 mM L-glutamine (Sigma), 100 U penicillin per ml, and 100 mg
streptomycin per ml (Gibco, Paisley, U.K.). Cells were incubated in a
humidi¢ed atmosphere of 5% CO2 and 95% air at 371C.
Human embryonic kidney (HEK293) cells were kindly supplied by
Professor R.J. Ross (Section of Medicine, Division of Clinical Sciences,
University of She⁄eld, U.K.). Cells were grown in 24-well plates in
Dulbecco’s modi¢ed Eagle’s medium supplemented with 10% fetal bovine
serum, 2 mM L-glutamine, 100 U penicillin per ml, and 100 mg
streptomycin per ml.
Normal primary human keratinocytes were established from full-
thickness skin obtained from abdominoplasty operations as described
previously (Goberdan et al, 1993). Brie£y, keratinocytes were harvested
from skin tissue pretreated with trypsin^ethylenediamine tetraacetic acid
(EDTA) (18 h) and cultured with De¢ned Keratinocyte Medium (SFM,
Gibco, U.K.) on type I rat tail collagen at 31 ml per cm2. First passage
keratinocytes were used for experimentation.
Experimental conditions Cells were kept proliferative and
experimentation started when cells reached 60% con£uence. All peptides
were from Bachem (Bubendorf, Switzerland): a-MSH, MSH 11^13 (L-K-
L-P-L-V), MSH 11^13 (L-K-L-P-D-V), ACTH 1^17, or ACTH 1^39 (10^7
M to 10^13 M) were added to cells for an incubation period of 15 min
followed byTNFa (Boehringer-Mannheim, Lewes, U.K.) addition (2.0 ng
per ml). Cells were incubated for a further 60 min, medium removed, and
washed with phosphate-bu¡ered saline (PBS) three times, ¢xed with 2%
paraformaldehyde (BDH Chemicals, Poole, U.K.) for 10 min, washed again
with PBS ( 3) and permeabilized using 0.1%Triton X100 (BDH) for
20 min, washed with PBS ( 3), and then neutralized with 50 mM
ammonium chloride (BDH) in PBS for 10 min.
Immuno£uorescent labeling of NFjB/p65, MC-1R, MC-2R, and
inhibitor kBa of NFjB (IjBa) Cells were permeablized for immuno-
labeling of NFkB/p65 or IkBa with Triton-X100 (0.1% wt/vol). Non-
permeablized cells were used for MC-1R or MC-2R immunolabeling.
After permeabilization, samples were washed with PBS ( 3) and
nonspeci¢c protein sites were blocked using 5% dried-milk powder (in
PBS, 1 h). Cells were then incubated with the appropriate primary
antibody: (a) anti-NFkB/p65 (C-20) goat polyclonal IgG antibody (sc-109,
Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h at room temperature
and pressure (1:100 vol/vol, in PBS); (b) anti-IkB-a (C-21) rabbit polyclonal
IgG antibody (sc-371) for 1 h at room temperature and pressure (1:100 vol/
vol, in PBS); (c) anti-MC-1R (N-19) goat polyclonal IgG antibody (sc-
6875) for 18 h at 41C (1:50 vol/vol, in blocking bu¡er/PBS); or (d) anti-
MC-2R (C-16) goat polyclonal IgG (sc-6876) for 18 h at 41C (1:50 vol/
vol, in blocking bu¡er/PBS). Cells were washed with PBS ( 3) and then
incubated with biotinylated anti-goat IgG antibody (BA-5000, Vector
Laboratories, CA, 1:1000 vol/vol in PBS) or biotinylated anti-rabbit IgG
antibody (BA-1000, Vector Laboratories) for 1 h at room temperature and
pressure, washed with PBS ( 3), followed by incubation with £uorescein
streptavidin (SA-5001,Vector Laboratories) 1:100 vol/vol in PBS for 30 min.
Cover slips were mounted using Vectashield mounting medium
(H-1300,Vector Laboratories) containing propidium iodide to label nuclei
(at 1.5 mg per ml). NFkB/p65 in normal human keratinocytes and HaCaT
cells were observed visually using epi£uorescent microscopy with
di¡erential Pinkel ¢lter sets for £uorescein (NFkB/p65: lex¼ 494 nm,
lem¼ 518 nm) and propidium iodide (nuclei: lex¼ 536 nm, lem¼ 617 nm).
Western immunoblotting analysis for MC-1R and MC-2R HaCaT
keratinocytes, normal human keratinocytes, and HEK293 cells were seeded
into six-well plates at 105 cells per well and grown until 60% con£uent.
Total cellular protein was then extracted for protein measurement
(assessed using bicinchoninic acid assay kit; Pierce, Rochford, IL) and the
remainder of the extract was incubated at 1001C for 2 min in a 75 mM
Tris^HCl bu¡er pH 6.8 (containing 15% sodium dodecyl sulfate, 5% b-
mercaptoethanol, 20% glycerol, 0.001% bromophenol blue). Fifteen
micrograms of total protein was loaded per gel track and samples were
electrophoresed according to the method of Laemmli (1970) (Mini
Protean II dual slab cell, Bio-Rad, Hemel Hempstead, UK) using a 5%
stacking gel and 10% resolving gel for 1 h (200 V, constant voltage).
Proteins were transferred onto 0.45 mm nitrocellulose membrane
(according to the method of Towbin et al, 1979; using a Mini Trans-Blot
system, Bio-Rad; 100 V, constant voltage). MC-1R and MC-2R
immunoreactive bands were visualized as follows: unreacted binding sites
were blocked with 5% (wt/vol) commercial dried milk powder in TBST
(10 mM Tris^HCl, 0.15 M NaCl, 0.05% (wt/vol) Tween 20, pH 8.0),
followed by incubation with primary rabbit polyclonal IgG speci¢c
antibody to MC-1R (N-19, sc-6875) or MC-2R (C-16, sc-6876) (Santa
Cruz Biotechnology; diluted 1:50 vol/vol with 5% commercial dried
milk powder in TBST) for 18 h at 41C, washed with TBST (310 min),
and incubated with horseradish-peroxidase-conjugated goat antirabbit
secondary antibody diluted 1:2000 (vol/vol) in TBST (Dako, Cambridge,
U.K.) for 1 h at room temperature. Immunoreactive bands were visualized
using 3,30 -diaminobenzidine (0.4 mg per ml)/hydrogen peroxide (0.7 ml per
ml). Prestained electrophoresis molecular weight standard markers were
run in parallel for calibration purposes (SDS-7B, Sigma).
Transfection of HEK293 cells with MC-1R HEK293 cells were
transiently transfected by the Calcium Phosphate Transfection System
(Gibco) using a pRc/CMV-MC-1R plasmid (kindly donated by Professor
J.E.S.Wikberg, Uppsala University, Sweden). Cells were cotransfected with
a b-galactosidase plasmid for calculating transfection e⁄ciency. After
transfection, cells were cultured for a further 3 d and processed for
Western immunoblotting.
MSH receptor binding studies Normal human keratinocytes and
HaCaT keratinocytes were checked for their ability to bind a-MSH.
INHIBITION OF NFkB BY MSH ANDACTH PEPTIDES 1245VOL. 119, NO. 6 DECEMBER 2002
Binding assays were performed using the following modi¢cation of a
previously published method (Ghanem et al, 1988). Brie£y, 250103 dpm
of 125I-[Nle4, Dphe7]-a-MSH in 100 ml was added to 106 cells (100 ml)
previously mixed with [Nle4, Dphe7]-a-MSH (concentration ranging
from 1013 to 106 M) in PBS pH 7.2 containing 0.1% bovine serum
albumin, 6.25 mM Hepes, and 0.1% trasylol. After mixing, the tubes
were incubated at 371C for 45 min before cell separation by repeated
centrifugation and washing. The pellet-associated radioactivity was then
measured in a gamma counter.
Nuclear extraction and electrophoretic mobility shift assay
(EMSA) Following the above protocol for HaCaT cell treatment with
TNFa and a-MSH combinations, cells were harvested using a scraper
into 10 mM Hepes bu¡er (pH 7.9) containing 1.5 mM MgCl2, 10 mM
KCl, and 0.1% Nonidet p-40. Nuclear extracts were prepared as described
previously (Dignam et al, 1983). Brie£y, samples were centrifuged
(12,000 g, 5 min) and the pellet was suspended in 20 mM Hepes bu¡er,
pH 7.9, containing 1.5 mM MgCl2, 420 mM NaCl, 0.2 mM EDTA, 25%
glycerol, incubated on ice (10 min), and centrifuged (12,000 g, 5 min).
Supernatant was diluted in 20 mM Hepes bu¡er, with 0.05 M KCl,
0.2 mM EDTA, 20% glycerol, and centrifuged (12,000 g, 5 min).
Supernatant from the latter centrifugation (containing the nuclear
fraction) was measured for protein content using the bicinchoninic acid
technique (Pierce). Five micrograms of protein from each sample were
mixed with a reaction bu¡er (1 mM EDTA, 50 mM NaCl, 10 mM Tris)
containing 50 mg per ml poly(dI-dC) (Promega, Southampton, U.K.) and
end-labeled oligonucleotide probe.The NFkB probe was a 25-mer double-
stranded synthetic oligonucleotide (VH Bio, Gosforth, U.K.) containing
the kB motif (50 -TGACAGAGGGGACTTCCGAGAGGA-30). End-
labeling was byT4 polynucleotide kinase (Promega) reaction with [g-32P]
ATP (NEN, Brussels, Belgium). Samples were loaded onto a 4%
polyacrylamide gel (38:1) in 1TBE (prerun for 30 min) and run at
100 V for 1 h, at 41C. Gels were dried and exposed to ¢lm (Amersham
hyper¢lm) for 18 h at ^701C with intensifying screens (Hypercassette,
Amersham, Little Chalfunt, UK). Quanti¢cation of NFkB activity was
by scanning densitometry of the p50/p65 speci¢c gel shift band (as a ratio
of the excess unbound radio labeled oligonucleotide band, as internal
control) using a GS-700 imaging densitometer in transmittance mode
integrating optical density and cross-sectional area, using Molecular
Analyst software (600 dpi, Bio-Rad).
Determination of NFjB binding speci¢city and subunit
composition Cells were treated as described above, stimulated with or
without TNFa (2.0 ng per ml) for 60 min, and then the nuclear fraction
was extracted. An excess of cold native oligonucleotide (100 M) was added
in addition to radiolabeled oligonucleotide in the sample binding reaction
described above, prior to running samples as before. In addition, an excess
of cold mutant oligonucleotide was also used (containing two base pair
mutations (GA-CT) of the native oligonucleotide probe: 50 -TGACA-
GAGGGCTCTTCCGAGAGGA-30). For identi¢cation of subunit
composition, nuclear extracts were incubated with rabbit polyclonal
antibodies (Santa Cruz Biotechnology) against the p65 or p50 NFkB
subunits.
Statistics Student’s paired t test was used to analyze data for identical
cellular treatments between control untreated and treated samples.
RESULTS
MC-1R and MC-2R immunolabeling in normal human
keratinocytes, HaCaT keratinocytes, and HEK293
cells Positive immunolabeling for the human MC-1R was
identi¢ed on the surface of nonpermeabilized normal human
keratinocytes (Fig 1a). Positive immunolabeling was also
identi¢ed for the MC-2R (Fig 1b). For both MC-1R and MC-
2R we observed the immunolabeling position to be similar,
exhibiting an even distribution over the surface membrane of
each cell under high magi¢cation (100, oil immersion
objective lens). Captured photographic images give the
impression of a ‘‘perinuclear’’ concentration. This observation can
also be seen by eye and is more so due to the very small focal
depth described by the microscope optics rather than a true
description of receptor distribution. Alteration of the focal plane
readily revealed membrane immunolabeling immediately above
the nucleus position for both MC-1R and MC-2R. No
detection was observed when primary anti-MC-R antibodies
were substituted with isotype IgG immunosera (Fig 1c,
micrograph illustrates counter labeling of nuclei for orientation
purposes with an absence of MC-R labeling).
HaCaT keratinocytes were also observed to label positively for
MC-1R, exhibiting a similar punctate labeling appearance evenly
distributed across the membrane surface (Fig 1d). In contrast to
normal keratinocytes, a weaker positive labeling for MC-2Rwas
identi¢ed (Fig 1e). Minor di¡erences in labeling intensity are
interpreted with some caution in relation to relative levels of
receptor expression; however, we would suggest that if HaCaT
keratinocytes express MC-2R the level of expression is very low.
These cells did not label when isotype IgG antisera were used in
place of primary anti-MC-R (Fig 1f, micrograph counterlabeling
of nuclei alone illustrated).
Non-transfected HEK293 cells were used as a negative control,
as these cells are reported not to express the MC-1R (Tsatmali
et al, 1999). It was observed, however, that HEK293 cells
exhibited a degree of positive MC-1R immunolabeling (Fig
1g). In comparison, the normal human keratinocytes and HaCaT
keratinocytes exhibited substantially higher immunolabeling
intensity (Fig 1a, d versus 1g). This suggests that either the
primary antibody used exhibits a degree of cross-reactivity, or
that a small degree of MC-1R expression arises in this cell type.
It was noted that very little immunolabeling was present for the
MC-2R of HEK293 cells (Fig 1h, counterlabeling for nuclei
alone shown). Furthermore, negative labeling was observed
when isotype IgG serum was used in place of a primary
antibody (Fig 1i, counterlabeling for nuclei alone shown).
Western immunoblotting of normal human keratinocytes,
HaCaT keratinocytes, and HEK293 cells for MC-1R and
MC-2R Western immunoblotting of normal human
keratinocytes (Fig 2, lane 3) and HaCaT keratinocyes (Fig 2, lane
4) for the MC-1R identi¢ed a single immunoreactive product at
a molecular weight of 35 kDa (indicated by arrow adjacent to
lane 4). This corresponds to the predicted molecular size for the
Figure1. Immunolabelling of keratinocytes for melanocortin re-
ceptor expression. Immuno£uorescent microscopic labeling of normal
human keratinocytes for (a) MC-1R and (b) MC-2R, and (c) an absence
of labeling for isotype control sample (nuclei labeled with propidium io-
dide shown). (d) Immunolabeling of HaCaT keratinocytes for the MC-1R,
with (e) weaker labeling for the MC-2R and (f ) no labeling for isotype
control samples (labeled nuclei shown). (g) Weak immunolabeling of
HEK293 cells for MC-1R and (h) no labeling for MC-2R or (i) in isotype
control samples (labeled nuclei shown). Scale bar: 10 mM.
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MC-1R. In addition, Western blots labeled for the MC-2R
revealed a major immunoreactive band observed for both
normal human keratinocytes (Fig 2, lane 5) and HaCaT
keratinocytes (Fig 2, lane 6) at 39 kDa, corresponding closely to
the predicted molecular weight of 34 kDa for the MC-2R. To
con¢rm immunoreactive speci¢city of Western blotting for
the MC-1R, nontransfected HEK293 cell sample extracts were
immunolabeled in parallel with HEK293 cells that were
transiently transfected with a pRc/CMV-MC-1R expression
vector. We observed that nontransfected cells did immunolabel
very faintly for a 35 kDa product (Fig 2, lane 1), suggesting that
HEK293 cells may actually express very low levels of MC-1R
protein (somewhat supportive of immuno£uorescent micro-
scopy data); however, MC-1R transiently transfected cells
demonstrated an identical size immunoreactive product, but
with a very much higher band labeling intensity (Fig 2, lane 2;
all sample lanes contained 15 mg total cellular protein loaded per
gel track). It is worth noting that higher molecular weight bands
were identi¢ed by the anti-MC-1R antibody, suggestive of the
possibility of cross-reactivity with non-MC-1R protein.
MSH receptor binding The HaCaT keratinocytes demon-
strated a speci¢c ability to bind to the MSH receptor and com-
pete with radiolabeled [Nle4, D-Phe7]-a-MSH (Fig 3). The
appearance of low-a⁄nity binding sites was observed
approximating 400^600 sites per cell, indicating the potential of
HaCaT keratinocytes to bind a-MSH. (Receptor binding studies
were conducted for normal human keratinocytes but insu⁄cient
numbers of cells prevented an accurate binding assay.)
a-MSH inhibits TNFa-stimulated NFjB activity in HaCaT
keratinocytes No basal NFkB binding activity was detected
for unstimulated HaCaT keratinocytes by EMSA analysis
(Fig 4a, lane 1); however, acute addition of TNFa (2.0 ng per
ml, 30 min or 60 min incubation) showed a marked increase in
the DNA-binding activity of a putative NFkB complex (Fig 4a,
lanes 5, 6). An identical sample stimulated with TNFa (2.0 ng per
ml, 1 h) together with 100 molar of excess cold NFkB
oligonucleotide showed speci¢c competition for the NFkB^
DNA-binding complex (indicated by upper arrow), resulting in a
reduction of radiolabeling intensity of the binding product (Fig
4a, lane 3). Incorporation of 100 molar excess of mutant
oligonucleotide (containing a double base pair mutation GA-
CT in the signal motif recognition site) was demonstrated not to
compete for binding (Fig 4a, lane 4). Typical results obtained by
EMSA analysis demonstrating the inhibitory action of a-MSH
on NFkB binding activity, where HaCaT keratinocytes were
incubated for 1 h with TNFa (2.0 ng per ml) and a-MSH
(1010 M or 109 M) in combination, are shown in Fig 4(a)
(lanes 7 and 8, respectively). a-MSH alone had no e¡ect on the
basal NFkB activity [Fig 4a, lane 2, data shown for a-MSH
(109 M)]. Supershift analysis using polyclonal antisera revealed
the DNA-binding complex was a p50/p65 heterodimer (data not
shown). Scanning densitometry for the NFkB^p50/p65 complex
is shown in histogram form in Fig 4(b).
Figure 2. Melanocortin receptor expression in keratinocytes. Immu-
nowestern blotting for the MC-1R (lanes 1^4) and MC-2R (lanes 5, 6). Lane
M, SDS-7B molecular weight marker; lane 1, nontransfected HEK293
cells; lane 2, HEK293 cells transfected with the human MC-1R; lanes 3, 5,
normal human keratinocyte cell extract; lanes 4, 6, HaCaT keratinocyte cell
extract. Fifteen micrograms of total protein was loaded per gel track.
Figure 3. Receptor binding of Nle4-D-Phe7-MSH to putative MSH
receptors on the surface of HaCaT keratinocytes. Measurements were
performed in triplicate (means7SEM) of three separate experiments.
Figure 4. Inhibition of TNF-a stimulated NF-jB activity in HaCaT
keratinocytes by a-MSH. (a) EMSA of HaCaT keratinocyte nuclear ex-
tracts (5 mg protein per gel track). EMSA shows a-MSH 1^13 inhibiting
NFkB p50/p65 activation by TNFb. Lane 1, control (no stimulation of
HaCaTcells); lane 2, a-MSH (109 M, 60 min); lane 3,TNFa (2.0 ng per ml,
60 min)+100 M excess cold native NFkB oligonucleotide; lane 4, TNFa
(2.0 ng per ml, 60 min)+100 M excess cold mutant oligonucleotide; lane 5,
TNFa (2.0 ng per ml, 30 min); lane 6,TNFa (2.0 ng per ml, 60 min); lane 7,
TNFa (2.0 ng per ml, 30 min)+a-MSH 1^13 (109 M); lane 8, TNFa (2.0
ng per ml, 60 min)+a-MSH 1^13 (109 M). Upper arrow (p50/p65) indicates
speci¢c NFkB p50/p65 complex. Lower arrow (NS) indicates nonspeci¢c
binding complex. (b) Scanning densitometry of the relative size and inten-
sity of the p50/p65 band of the NFkB complex (units, cm1).
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Inhibition of cytokine-stimulated NFkB activity was
investigated further by immunolabeling for the transcriptionally
active p65 subunit of NFkB. In unstimulated cells the NFkB/p65
subunit was positioned exclusively in the cytoplasm and, more
importantly, was absent from the nucleus (Fig 5a, d). The
intracellular position of NFkB has been described previously for
many cell types and is one method for observing acute, regulated
activity. Addition of the proin£ammatory cytokine TNFa to
HaCaT keratinocytes revealed a change in intracellular position
of the p65 subunit from the cytoplasm to the nucleus after 1 h
(Fig 5b, e). Nuclear position is due to speci¢c binding of p65
(either as heterodimer or homodimer) to NFkB-dependent
double-stranded gene promoter sequences. Maximum NFkB
activity was detected following incubation with TNFa for 60
min and at a concentration of 2.0 ng per ml. A 1 h incubation
time and 2.0 ng per ml concentration for TNFa-stimulated
activation of NFkB/p65 was adhered to rigorously for
subsequently investigating the inhibitory potential of a-MSH,
two MSH carboxyl-terminal tripeptide derivatives, and two
ACTH peptides in detail: (i) a-MSH 1^13 (native, full-length
sequence); (ii) MSH 11^13 (L-Lys-L-Pro-L-Val); (iii) MSH
11^13 (L-Lys-L-Pro-D-Val); (iv) ACTH 1^39 (native, full-length
peptide); and (v) ACTH 1^17 (ACTH peptide fragment).
Inhibition was identi¢ed by a reduction in the extent of nuclear
translocation for individual cells and also the number of cells in
which limited nuclear translocation was observed, compared with
cells stimulated withTNFa alone [Fig 5c, f, micrograph illustrates
limited NFkB/p65 nuclear translocation for cells coincubated
with a-MSH (109 M) and TNFa (2.0 ng per ml) for 60 min].
a-MSH 1^13 was observed to inhibit TNFa-stimulated
activation of NFkB maximally at 109 M (Fig 6a, closed triangles;
37% inhibition, p¼ 0.007, n¼ 3) and signi¢cant inhibition was
also observed at 108 M (32% inhibition, p¼ 0.009, n¼ 3).
a-MSH at concentrations of 1011 M (20% inhibition, p¼ 0.18,
n¼ 3), 108 M (26% inhibition, p¼ 0.06, n¼ 3), and 107 M
(22% inhibition, p¼ 0.07, n¼ 3) was found not to signi¢cantly
inhibit NFkB activation (Fig 6a). a-MSH 1^13 in the absence of
TNFa did not alter basal NFkB/p65 activity at any of the
concentrations investigated (Fig 6a, open triangles, n¼ 3). The
carboxyl-terminal tripeptide MSH 11^13 (L-Lys-L-Pro-L-Val)
signi¢cantly inhibited TNFa-stimulated NFkB activation at
109 M and 108 M with maximum inhibition at 107 M
(Fig 6a, closed circles; 44% inhibition, p¼ 0.0019, n¼ 3).
Concentrations of 106 M and 105 M did not inhibit
signi¢cantly (Fig 6a, n¼ 3). MSH 11^13 (L-Lys-L-Pro-L-Val) in
the absence of TNFa did not alter basal NFkB activity
signi¢cantly (Fig 6a, open circles; n¼ 3). The carboxyl-terminal
tripeptide MSH 11^13 (L-Lys-L-Pro-D-Val) inhibited NFkB/
p65 activation maximally at a concentration of 1011 M (Fig 6a,
open squares; 48% inhibition, p¼ 0.0002, n¼ 3). This peptide,
however, produced a signi¢cant inhibition of the response to
TNFa throughout the concentration range 1013 M to 107 M,
of the order of 30%^40%. MSH 11^13 (L-Lys-L-Pro-D-Val) in
Figure 5. Immuno£uorescent labeling of HaCaT keratinocytes for
the p65 subunit of NFjB, demonstrating relative transcription fac-
tor activity. (a, d) Control unstimulated HaCaT keratinocytes. Inactive
NFkB identi¢ed by intracellular cytoplasmic localization with no nuclear
immunolabeling. (b, e) TNFa (2.0 ng per ml) stimulated HaCaT keratino-
cytes (60 min). Active NFkB identi¢ed by rapid visual nuclear localization
(some cytoplasmic labeling evident). (c, f ) TNFa (2.0 ng per ml) stimulated
HaCaT keratinocytes +a-MSH 1^13 (at 109 M). Inhibited activation of
NFkB identi¢ed by a marked reduction in nuclear localization compared
with TNFa alone-stimulated cells. (a^c) NFkB/p65 labeled with FITC
(green) alone. (d^f) Dual labeled micrographs with NFkB/p65 (FITC) +
counterlabeled nuclei (propidium iodide, red). Scale bar: 100 mM.
Figure 6. Inhibition of TNF-a stimulated NF-jB activity in Kerati-
nocytes by POMC peptides. (a) Extent of inhibition by MSH peptides
on TNFa-stimulated activation of NFkB/p65 in human HaCaT keratino-
cytes. Cells were stimulated for 15 min with a-MSH 1^13 (m), MSH 11^13
L-Lys-L-Pro-L-Val (), or MSH 11^13 L-Lys-L-Pro-D-Val (J), followed
by stimulation withTNFa (2.0 ng per ml) for 60 min. E¡ectiveness of pep-
tide action alone in the absence of TNFa stimulation on NFkB/p65 is
shown for a-MSH 1^13 (&), MSH 11^13 L-Lys-L-Pro-L-Val (), or MSH
11^13 L-Lys-L-Pro-D-Val (+). Signi¢cance for a-MSH1^13 (), MSH11^13
L-Lys-L-Pro-L-Val (+), or MSH 11^13 L-Lys-L-Pro-D-Val ( n ): n//+,
po0.05; nn//++, po0.01; nnn//+++, po0.001. (b) Extent of inhibition by
ACTH peptides on TNFa-stimulated activation of NFkB/p65 in human
HaCaT keratinocytes. Cells were stimulated for 15 min with ACTH 1^17
(’) or ACTH 1^39 (), followed by stimulation with TNFa (2.0 ng per
ml) for 60 min. E¡ectiveness of peptide action alone in the absence of TNFa
stimulation on NFkB/p65 is shown for ACTH 1^17 (&) or ACTH 1^39
(J). None of the peptide concentrations studied signi¢cantly inhibited
TNFa-stimulated NFkB/p65 activation.
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the absence of TNFa did not alter basal NFkB/p65 activity at any
of the concentrations investigated (Fig 6a, closed squares). Neither
ACTH 1^39 (Fig 6b, closed circles, n¼ 3) or ACTH 1^17 (Fig 6b,
closed squares) achieved signi¢cant inhibition throughout the
concentration range 1013 M to 107 M, nor did they a¡ect basal
NFkB/p65 activity (Fig 6b, open circles and squares, respectively;
n¼ 3). The maximum potencies of the above POMC peptides
are shown inTable I.
Inhibition of NFjB/p65 by POMC peptides in normal
human keratinocytes The most e¡ective inhibitory
concentration of each POMC peptide identi¢ed above for
HaCaT keratinocytes was used to investigate inhibition of
normal human keratinocyte NFkB/p65 activity. This approach
was used so that all data obtained for normal human
keratinocytes were consistent in that they corresponded to a
single patient sample. Restriction on biopsy sample size limited
the investigation to single most e¡ective POMC dosages,
identi¢ed above for the HaCaT keratinocyte line. Signi¢cant
inhibition of TNFa-stimulated NFkB inhibition was observed
for all three MSH peptides. a-MSH 1^13 at 109 M was e¡ective
at inhibiting cytokine-stimulated NFkB activation by 15%
(Fig 7, p¼ 0.05, n¼ 3), MSH 11^13 (L-Lys-L-Pro-L-Val) at 107
Mwas e¡ective at inhibiting NFkB activity by 29% (Fig 7, 0.009,
n¼ 3), and MSH 11^13 (L-Lys-L-Pro-D-Val) at 1011 M was
e¡ective at inhibiting NFkB activity by 55% (Fig 7, p¼ 0.003,
n¼ 3). Interestingly, ACTH 1^39 at 109 M was observed to
signi¢cantly inhibit cytokine-stimulated NFkB/p65 at 109 M
by 25% (Fig 7, p¼ 0.01, n¼ 3), in contrast to a lack of
inhibition observed for this peptide in the HaCaT keratinocytes.
Inhibition of NFkB activity by 8% with ACTH 1^17 (at 109 M)
was not found to be signi¢cant (Fig 7, p¼ 0.24, n¼ 3), consistent
with a lack of inhibition identi¢ed in HaCaT keratinocytes.
Incubation of individual POMC peptides alone with normal
human keratinocytes (at the above stated concentrations) did
not signi¢cantly alter NFkB/p65 activity, compared with
unstimulated control cells (Fig 7).
IjBa regulation by POMC peptides in HaCaT and normal
human keratinocytes Unstimulated HaCaT keratinocytes
displayed a high degree of IkBa immunolabeling localized to
the nucleus of every cell observed, with considerably less
immunolabeling detected in the cytoplasm in comparison
(Fig 8a). The high degree of nuclear speci¢c labeling was
observed for all HaCaT cells without exception. HaCaT
keratinocytes were incubated for 60 min with individual POMC
peptides at the single most e¡ective concentration previously
identi¢ed to inhibit TNFa-stimulated NFkB activity after 60
min for this cell type. No di¡erences were identi¢ed in IkBa
immunolabeling intensity or nuclear versus cytoplasmic IkBa
positioning when cells were incubated with any of the above
peptides, in comparison with IkBa immunolabeling observed
for unstimulated control cells (Fig 8b^d; a-MSH, L-Lys-L-Pro-
L-Val, and L-Lys-L-Pro-D-Val, respectively; data not shown for
ACTH 1^39 or ACTH 1^17).
In contrast to HaCaT keratinocytes, unstimulated normal
human keratinocytes displayed a more heterogeneous
distribution of IkBa (Fig 9a). Hence, some isolated cells
displayed a high degree of immunolabeling localized to the
nucleus, some displayed an equal nuclear versus cytoplasmic
distribution and some cells displayed stronger immunolabeling
in the cytoplasm compared with the nucleus. Incubation with
the POMC peptides (at the single stated concentrations above)
for 60 min induced translocation of IkBa to the nucleus, in
contrast to the heterogeneous distribution for unstimulated cells.
Microscope ¢eld-of-view observations are shown for cells
incubated with each POMC peptide (Fig 9b^f ). With each
POMC peptide a higher degree of IkBa immunolabeling was
observed localized to the nucleus, in marked contrast to the
heterogeneous immunolabeling described for unstimulated cells;
however, due to the heterogeneous intracellular IkBa localization
of the unstimulated control cells, it was di⁄cult to make
quantitative comparisons of individual peptide potencies, but
a particularly high degree of nuclear versus cytoplasmic
immunolabeling was noted for cells incubated with L-Lys-L-
Table I. Comparison of the potency of MSH and ACTH peptides in inhibiting TNFa-stimulated NFkB/p65 activity
in HaCaT keratinocytesa
Peptide Maximum mean % inhibition7SEM Peptide concentration p
a-MSH 113 36.772.4 109 M 0.007nn
MSH 1113 (L-Lys-L-Pro-L-Val) 44.172.8 107 M 0.001nnn
MSH 1113 (L-Lys-L-Pro-D-Val) 48.073.2 1011 M 0.0002nnn
ACTH 117 11.776.9 1012 M 0.24 (NS)
ACTH 139 15.477.2 109 M 0.48 (NS)
aThe table shows the concentration of peptide that produced maximum inhibition of TNFa-stimulated NFkB/p65 activity in HaCaT keratinocyte cells. HaCaT kera-
tinocytes were exposed to 2.0 ng per ml TNFa for 60 min.Values show mean percentage inhibition7SEM achieved based on three separate experiments.
nnpo0.01; nnnpo0.001; NS, not signi¢cant.
Figure 7. Inhibition of TNFa-stimulated NFjB/p65 activity in
normal human keratinocytes by MSH/ACTH peptides. The most
e¡ective MSH/ACTH peptide was used, as previously identi¢ed from data
on HaCaT keratinocytes.
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Pro-L-Val (Fig 8c and 10^7 M) and L-Lys-L-Pro-D-Val (Fig 9d
and 1011 M).
DISCUSSION
The objective of this study was to examine the extent to which
nonpigmentary keratinocytes are protected from the e¡ects of
proin£ammatory cytokines by a-MSH and related POMC pep-
tides, and to investigate the role of IkBa as one potential inhibi-
tion mechanism. The key ¢ndings of this study are that MSH
peptides attenuate the response to TNFa-activated NFkB tran-
scription factor in normal keratinocytes and in a keratinocyte cell
line (HaCaT), but that di¡erences were seen in response of the
cell line and the normal cells with respect to ACTH peptide re-
sponses and regulation of IkBa. All MSH peptides and ACTH 1^
39 were e¡ective at inhibiting TNFa in normal human keratino-
cytes, whereas a truncated ACTH 1^17 peptide was ine¡ective.
MSH peptides and ACTH peptides enhanced nuclear transloca-
tion of the NFkB inhibitor IkBa to the nucleus in normal hu-
man keratinocyte cells.We suggest that this has the potential to
serve as an inhibitory mechanism for inhibition of NFkB by
the peptides studied. In contrast, HaCaT keratinocytes were iden-
ti¢ed to have an aberrant constitutive expression of IkBa in the
nucleus irrespective of stimulation. This is supportive of previous
data on a defective NFkB signaling pathway in this cell line
(Chaturvedi et al, 1999; Qin et al, 1999). This cell line was totally
unresponsive to ACTH peptides.
a-MSH is produced in a number of tissues of the body includ-
ing the pituitary gland, brain, and various extra neural tissues
such as skin (Eberle, 1988; 2000). Generation arises by sequential
proteolysis of the precursor molecule POMC by pro-hormone
convertase enzymes (PC1 and PC2/7B2) (Benjannet et al, 1991).
Other POMC-generated molecules include b-endorphin, b-lipo-
trophin, and ACTH. a-MSH signaling is by a receptor-mediated
mechanism via the MC receptor family. Five MC receptors have
been cloned (MC-1R to MC-5R) and MC-1R has highest a⁄-
nity for a-MSH and is expressed on a number of cells including
melanocytes, ¢broblasts, and endothelial cells (Chhajlani and
Wikberg, 1992; Mountjoy et al, 1992). MC-2R is expressed on
the surface of adrenal cortical cells (and binds ACTH with high
a⁄nity), MC-3R is located on cells of the brain, placenta, and
gut, MC-4 is expressed widely on nerve tissue, and MC-5 is ex-
pressed in a number of peripheral tissues. The MC-1R can signal
by activating adenyl cyclase coupled to elevated levels of cAMP. It
is by this signaling mechanism that a-MSH in skin tissue, via the
MC-1R expressed on melanocytes, is thought to initiate the pro-
duction of eumelanin, responsible for cutaneous pigmentation
(Burchill et al, 1986; 1993).
Immunolabeling microscopy revealed that the MC-1R was
present on the surface of normal and immortalized HaCaT kera-
tinocytes; however, HEK293 cells (reported not to express MC-
1R) also labeled, albeit less intensely.We suggest that either the
anti-MC-1R antiserum used exhibits a degree of cross-reactivity
to non-MC-1R sites or that HEK293 cells express a small degree
of MC-1R. At present only one commercial source of anti-MC-
1R exists to the best of our knowledge.Western immunoblotting
identi¢ed a 35 kDa immunoreactive product present for normal
human keratinocyte and HaCaT cells. Furthermore, HEK293
transiently transfected cells with MC-1R demonstrated an in-
crease in intensity for the same reactive product. Untransfected
cells showed a faint immunolabeling product suggesting very
low MC-1R expression. Normal human keratinocytes immuno-
labeled strongly for MC-2R and had an immunoreactive
Western blot band at 39 kDa. Although the predicted molecular
Figure 8. Immuno£uorescence microscopy of IjBa in HaCaT kera-
tinocytes stimulated with MSH peptides for 60 min, showing intra-
cellular localization. (a) Control, untreated cells. Cells stimulated with
(b) a-MSH 1^13 (at 109 M), (c) MSH 11^13 L-Lys-L-Pro-L-Val (107 M),
and (d) MSH 11^13 L-Lys-L-Pro-D-Val (1011 M).
Figure 9. Immuno£uorescence microscopy of IjBa in normal
human keratinocytes stimulated with MSH/ACTH peptides for
60 min, showing intracellular localization. (a) Control, untreated cells.
Cells stimulated with (b) a-MSH 1^13 (109 M), (c) MSH 11^13 L-Lys-L-
Pro-L-Val (107 M), (d) MSH 11^13 L-Lys-L-Pro-D-Val (1011 M), (e)
ACTH 1^39 (109 M), and (f) ACTH 1^17 (109 M).
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size is 34 kDa we suggest that this discrepancy is due to anoma-
lous electrophoretic migration. In contrast, HaCaTcells had weak
MC-2R immunolabeling, but whereas a reactive 39 kDa product
was detected suggesting a degree of receptor presence, HEK293
cells did not label at all for MC-2R indicating antibody speci¢-
city.
MSH receptor binding assay revealed that the HaCaT keratino-
cyte could potentially contain between 400 and 600 receptors per
cell, approximately the number of sites per cell previously de-
scribed for normal human melanocyte cells (Donatien et al,
1992); however, variation was observed between experiments
possibly suggesting that the keratinocyte might regulate the
number of MC-1R expressed.This has previously been suggested
for keratinocytes in regard to di¡erentiation status (Chakraborty
et al, 1999) and in melanocytes in response to exogenous factors
such as endothelin-1 (Ermak and Slominski, 1997) and ultraviolet
B (Funasaka et al, 1998). Normal human keratinocytes did not
competitively bind MSH on the samples processed; however, data
were obtained from the same source as that used for functional
NFkB and IkBa studies and hence results were from a limited
number of cells in late passage. Normal human keratinocytes,
however, have been previously reported to express the MC-1R
(Chakraborty et al, 1999).
The number of di¡erent tissues where a-MSH is released and
where MC-R are expressed has led investigators to suggest roles
other than cutaneous pigmentation and it is widely reported that
a-MSH can inhibit fever, in£ammation, and secretion of C reac-
tive protein (Hiltz and Lipton, 1989; Hiltz et al, 1991; Lipton et al,
1991; 1998; Martin et al, 1991; Catania and Lipton, 1993;Watanabe
et al, 1993; Ceriani et al, 1994; Bhardwaj et al, 1996; Lipton and Cat-
ania, 1997; Orel et al, 1997; Rajora et al, 1997; Kalden et al, 1998a;
1998b; B˛hm et al, 1999; Ichiyama et al, 1999b; Taherzadeh et al,
1999). In£ammatory inhibition is thought to arise by an a-MSH
signaling pathway that results in inhibiting the production or ac-
tion of a number of proin£ammatory cytokines [e.g., TNFa
(Morandini et al, 1998), IL-1b (Weiss et al, 1991), or IL-6 (Martin
et al, 1991)]. Evidence also exists on a-MSH directly stimulating
the production of the IL-10 anti-in£ammatory cytokine (Bhard-
waj et al, 1996).We focused speci¢cally on inhibition of TNFa-
activated NFkB activity in the human HaCaT keratinocyte cell
line by ¢ve POMC peptides: (i) a-MSH 1^13 (native, full-length
sequence); (ii) MSH 11^13 (L-Lys-L-Pro-L-Val); (iii) MSH 11^13
(L-Lys-L-Pro-D-Val); (iv) ACTH 1^39 (native, full-length pep-
tide); and (v) ACTH 1^17 (ACTH peptide fragment). Con¢rma-
tion of POMC actions on NFkB was repeated in normal human
keratinocytes.The intracellular position of the NFkB p65 subunit
was tracked and activation assessed according to observed intra-
cellular position for both cell types. [The presence of a transacti-
vating domain on p65 (as opposed to p50) made this the subunit
of choice for immunolabeling, as p65 nuclear translocation is a
positive indication of transcriptional activation upon binding to
target nuclear consensus sequences (Baeuerle and Henkel, 1994).]
POMC peptides with inhibitory potential were observed to re-
duce the extent of nuclear translocation of NFkB for a given cell
and the number of cells as a proportion of the total population in
which NFkB translocation was inhibited. Both observations were
included in calculating a relative level of NFkB activity. EMSA
analysis on nuclear extracts was used to substantiate immunola-
beling data for NFkB/p65.
The most e¡ective inhibitory concentration of the full-length
peptide in HaCaT keratinocytes was 109 M and a biphasic dose-
dependent inhibitory action was observed such that a-MSH con-
centrations higher or lower than 109 M were less e¡ective. The
e¡ective potency and biphasic inhibition correlates with other
studies on NFkB inhibition by a-MSH for other cell types (e.g.,
glioma cells; Manna and Aggarwal, 1998; B˛hm et al, 1999;
Ichiyama et al, 1999b). Furthermore, a biphasic dose^response
curve is also observed for a number of other inhibitory actions,
e.g., inhibition of pyresis, cutaneous in£ammation, surface
ICAM-1 upregulation, inhibition of reactive species generation,
and glutathione peroxidase activation (Lipton et al, 1991; Martin
et al, 1991; Catania and Lipton, 1993;Watanabe et al, 1993; Ceriani
et al, 1994; Lipton and Catania, 1997). Data obtained for the term-
inal MSH11^13 tripeptide sequence L-Lys-L-Pro-L-Val also sup-
ported an inhibitory action on cytokine-stimulated NFkB.
Although this was approximately 100 times less potent than a-
MSH 1^13, a biphasic dosage curve of inhibition was also ob-
served. The MSH 11^13 tripeptide sequence L-Lys-L-Pro-D-Val
proved to be approximately 100 times more potent than a-MSH
1^13 peptide, with maximum inhibition of NFkB at 1011 M.
Furthermore, signi¢cant levels of inhibition were also noted for
concentrations ranging from 107 M to 1013 M. The C-terminal
tripeptide sequence of a-MSH has previously been reported as
the minimal sequence necessary to elicit an anti-in£ammatory re-
sponse (Hiltz et al, 1991). Our data on inhibition of NFkB by
L-Lys-L-Pro-L-Val and L-Lys-L-Pro-D-Val in HaCaT keratino-
cytes con¢rms previous work that these tripeptides have potential
to inhibit an intracellular in£ammatory pathway.
HaCaT keratinocytes incubated with either ACTH 1^39 or
ACTH 1^17 were found to have normal levels of NFkB activity
when challenged with TNFa. The unresponsiveness of either
ACTH peptide at inhibiting NFkB supports a speci¢c role of
the MSH peptides in these cells. ACTH 1^39 binds and acts
through the MC-2R by elevating intracellular cAMP. Although
a speci¢cWestern immunolabeled product was identi¢ed for Ha-
CaT cells, immuno£uorescent labeling of nonpermeabilized cells
was very weak. The lack of a response to ACTH 1^39 might
therefore be attributable to a low receptor expression.
The most e¡ective MSH peptide concentrations identi¢ed at
inhibiting HaCaT keratinocyte NFkB activity were con¢rmed
using normal keratinocytes from a single patient human donor.
a-MSH, L-Lys-L-Pro-L-Val, and L-Lys-L-Pro-D-Val were all
e¡ective at inhibiting NFkB activation. In contrast to HaCaT
cells, normal human keratinocyte NFkB activity was inhibited
byACTH 1^39 and ACTH 1^17 was ine¡ective. The normal hu-
man keratinocyte cells were observed to immunolabel strongly
for MC-2R and have a 39 kDaWestern blot product. Thus, it is
possible that ACTH 1^39 is acting through the MC-2R to inhi-
bit NFkB.
The immunomodulatory actions of a-MSH are thought to
arise via the MC-1R; however, the mechanism by which the
MSH 11^13 peptide acts is at present unresolved. On the one
hand studies support a similar biology between a-MSH and
MSH 11^13; however, studies also report that MSH 11^13 does
not bind to either the MC-1R (Morandini et al, 1994;Wikberg et
al, 2000) or indeed MC-3, MC-4, or MC-5R (Wikberg et al,
2000). Functional studies show that MSH 11^13 is ine¡ective in
the lizard skin assay (which measures pigment redistribution)
and adenylate cyclase assay in Cloudman S91 mouse melanoma
cells (Sawer et al, 1988). An alternative explanation of a nonmela-
nocortin receptor mechanism thus appears possible, especially in
the light of work demonstrating that MSH 11^13 can inhibit
NFkB activation in the central nervous system of mice with mu-
tant MC-1R (Ichiyama et al, 1999a). Evidence for such an MC-
1R-independent mechanism has previously been described for
a-MSH in control of pigmentation in melanocyte cells (Moore
et al, 1999; Peters et al, 2000), suggesting that the peptide, rather
than being involved in receptor binding/activation, binds directly
to the tyrosinase enzyme. This issue is yet to be resolved. In this
study responses to MSH 11^13 were observed over a similar time
course of action as for the full-length peptide. Other possible
routes of action include it acting as a proin£ammatory cytokine
receptor antagonist, as previously reported for IL-1b193^195, which
contains the sequence Lys-D-Pro-Val (Haddad et al, 2001). The
identical amino acid sequence may have TNFa receptor antago-
nist properties.
Some POMC peptides are more abundant in skin tissue than
a-MSH (Wakamatsu et al, 1997), in particular ACTH 1^17. In
HEK293 cells transfected with the human MC-1R ACTH 1^17
is slightly more e¡ective than acetyl a-MSH at elevating intracel-
lular cAMP (Tsatmali et al, 1999). The binding a⁄nity to the MC-
1R is also similar (Ki¼ 0.13 nM versus 0.21 nM); however, ACTH
INHIBITION OF NFkB BY MSH ANDACTH PEPTIDES 1251VOL. 119, NO. 6 DECEMBER 2002
1^17 is unusual in stimulating inositol trisphosphate (IP3) produc-
tion, in contrast to a modest stimulatory production by a-MSH.
Data from our study show that ACTH 1^17 is ine¡ective at inhi-
biting TNFa-stimulated NFkB activity, in contrast to the three
MSH peptides.
The question therefore arises why the MSH peptides are e¡ec-
tive at inhibiting NFkB activation when the ACTH peptides are
not. ACTH is known to have its highest a⁄nity for the MC-2R,
expressed on the surface of adrenal cortical cells.We are not aware
of whether the ACTH 1^17 fragment has a higher a⁄nity for
MC-1 or for MC-2R; however, it was of interest to note that
we observed positive labeling of the MC-2R on the surface of
nonpermeabilized normal keratinocytes. Thus, it is possible that
a-MSH signaling via MC-1 induces a cAMP signal that can
cause both pigmentation and inhibition of cytokine-stimulated
NFkB activity in cells with pigmentation potential, and inhibi-
tion of NFkB activation in cells that do not pigment, and that
ACTH via MC-2R can also inhibit NFkB activity. As previously
reported, the ACTH 1^17 peptide stimulates a dual signal (cAMP
and IP3) via the MC-1R in contrast to a-MSH.We know that a-
MSH can activate protein kinase C in melanoma cells (Bu¡ey
et al, 1992) and increase intracellular calcium when the MSH-in-
duced cAMP pathway is suppressed (Smith-Thomas et al, 2001).
As generation of an IP3 signal is known to inhibit the cAMP
pathway, inhibition of cytokine-stimulated NFkB activation
would not be expected to arise as a result, as observed (as we
and other investigators have previously reported NFkB
inhibition by the cAMP pathway using receptor-independent
agents such as forskolin and isobutyl methylxanthine, which ele-
vate cAMP; Ollivier et al, 1996; Haycock et al, 1999a). Alterna-
tively, the ACTH 1^17 peptide may signal via surface MC-2R
as well as MC-1R and inhibition of an MC-1-generated
signal might arise via an MC-2 pathway. This is at present
unresolved.
It has been previously reported that the HaCaT keratinocyte
cell line has an altered NFkB signaling pathway compared with
normal human keratinocytes (Chaturvedi et al, 1999; Qin et al,
1999). Here, proliferating unstimulated cells are reported to have
constitutively active NFkB (p50/p65) nuclear binding activity,
which does not alter in response to g-interferon or tissue plasmi-
nogen activator. This is in contrast to normal human keratino-
cytes, which display a normally regulated activity in this respect.
NFkB transactivation potential is also reported as reduced in the
HaCaT cells (by standard transactivation luciferase reporter gene
assay). Our ¢ndings contrast that of Qin et al in that proliferating
unstimulated HaCaTcells do not have constitutive DNA-binding
activity by both immuno£uorescent microscopy (absence of
NFkB/p65 in nuclei) and EMSA analysis. We also found that
NFkB/p65 is regulated in response to a cytokine stimulus with
TNFa causing rapid nuclear translocation, again observed by im-
muno£uorescent microscopy and EMSA DNA binding.We are
unsure as to the discrepancy, but suggest that the standard normal
human keratinocyte growth medium used by Qin et al to culture
HaCaT keratinocytes contains factors with potential to activate
NFkB, in contrast to our use of a basic medium with minimal
supplements. Regulated NFkB activity is observed between 0
and 60 min (i.e., the time taken to activate by TNFa); however,
we suggest signaling distal to this activation may be aberrant, in
agreement with Qin et al as they report no transcriptional activity
with an NFkB reporter construct. In support of this we have
identi¢ed that IkBa is constitutively expressed in the HaCaT cell
nucleus. This defective IkBa position would suggest an ability to
bind to active NFkB when translocated to the nucleus, thereby
preventing further continuity of this pathway. We suggest that
the ability of IkBa to translocate to the nucleus is one potential
mechanism by which a-MSH/ACTH may act to inhibit NFkB.
In contrast, unstimulated normal human keratinocyte cells had a
heterogeneous distribution of IkBa between nucleus and cyto-
plasm and all POMC peptides (including ACTH 1^17) used in
isolation had the capacity to induce nuclear translocation within
60 min. This mechanism of IkBa translocation has previously
been described for a nitric-oxide-induced mechanism of NFkB
inhibition in endothelial cells (Spiecker et al, 1997).
In summary, we have demonstrated that full-length a-MSH is
e¡ective at inhibiting cytokine-stimulated transcription factor
NFkB activity in a nonpigmentary keratinocyte cell-line. MSH
11^13 L-Lys-L-Pro-L-Val achieved a similar degree of inhibition
but was approximately 100 times less potent than the full-length
peptide. In contrast, MSH 11^13 L-Lys-L-Pro-D-Val was as e¡ec-
tive as native a-MSH in terms of extent of inhibition achieved,
but was 100 times more potent.We suggest that the more likely
hypothesis to account for the e¡ectiveness of MSH peptides and
relative ine¡ectiveness of ACTH peptides in modulating the re-
sponse to TNFa is cross-talk between signaling pathways. Irre-
spective of the detailed mechanism involved this study provides
clear evidence that the protective actions of the MSH peptides
extend to normal and immortalized keratinocytes.
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